MEDI4736

Known as: Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736 
 

Topic mentions per year

Topic mentions per year

2013-2017
051020132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
PURPOSE To investigate the safety and efficacy of durvalumab, a human monoclonal antibody that binds programmed cell death ligand… (More)
Is this relevant?
2016
2016
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 (PD-L1) monotherapies have shown promising clinical activity… (More)
  • figure 1
  • table 1
Is this relevant?
2015
2015
Programmed cell-death 1 ligand 1 (PD-L1) is a member of the B7/CD28 family of proteins that control T-cell activation. Many… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Background As single agents, durvalumab (MEDI4736), a human IgG1 anti-PD-L1 antibody, and tremelimumab, a human IgG2 anti-CTLA-4… (More)
  • table 1
Is this relevant?
Review
2015
Review
2015
MEDI4736 is a human immunoglobulin (Ig) G1к monoclonal antibody that blocks programmed cell death ligand-1 (PD-L1) binding to its… (More)
Is this relevant?
2015
2015
Melanoma was again a focus of attention at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, in particular… (More)
  • table 1
  • table 2
Is this relevant?
2015
2015
Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus… (More)
  • figure 1
Is this relevant?
2015
2015
Background Patients with R/M SCCHN have a poor prognosis, and current therapies used after failure of first-line platinum-based… (More)
  • figure 1
Is this relevant?
2014
2014
Results NCT01693562: As of May 2014, NSCLC cohort included 155 patients (pts) (median age 65 years [3385], PS 0/1/unknown [25%/73… (More)
  • figure 1
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Modulation of the immune system by targeting coinhibitory and costimulatory receptors has become a promising new approach of… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?